HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $350
Benzinga Newsdesk 47 minutes ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $280 to $350.
HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $280 to $350.